Reasons for Treatment (Tx) Discontinuation Among Hepatitis C (HCV) Patients Treated in Clinical Practice

被引：0
|
作者：
Yood, Marianne Ulcickas [1 ]
Sapra, Sandhya [2 ]
Oliveria, Susan A. [1 ]
Casso, Deborah [1 ]
Fu, An-Chen [3 ]
L'Italien, Gilbert [2 ]
机构：
[1] EpiSource, Newton, MA USA
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
[3] HealthCore, Wilmington, DE USA
来源：
HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1746
引用
收藏
页码：1005A / 1005A
页数：1
相关论文
共 50 条
  • [1] VIROLOGIC RESPONSE AMONG HEPATITIS C (HCV) PATIENTS TREATED IN CLINICAL PRACTICE
    Yood, Marianne Ulcickas
    Sapra, Sandhya
    Oliveria, Susan A.
    Casso, Deborah
    Cziraky, Mark
    Fu, An-Chen
    L'Italien, Gilbert J.
    HEPATOLOGY, 2011, 54 : 875A - 876A
  • [2] A Study to Understand the Reasons for Early Treatment Discontinuation among People Living with Hepatitis C in Punjab, India
    Mutreja, Karishma
    Boeke, Caroline E.
    Tandon, Roli
    Witschi, Magdalena
    Sindhwani, Siddharth
    Chawla, Umesh
    Gaugna, Shalu
    Grover, Gagandeep Singh
    INDIAN JOURNAL OF PUBLIC HEALTH, 2025, 69 (01) : 3 - 9
  • [3] Premature Discontinuation of Direct Acting Antiviral (DAA) Therapy in Patients with Chronic Hepatitis C Virus (HCV) in Real World Clinical Practice
    Hanifi, Jasmine M.
    Lin, Ming V.
    HEPATOLOGY, 2016, 64 : 976A - 976A
  • [4] REASONS FOR DISCONTINUATION OF TOFACITINIB IN REAL CLINICAL PRACTICE
    Aronova, E.
    Gridneva, G.
    Dydykina, I.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S140 - S140
  • [5] USE OF TOFACITINIB AND REASONS FOR DISCONTINUATION IN CLINICAL PRACTICE
    Soleto, C. Y.
    Serrano Benavente, B.
    Torrens Cid, L. A.
    Martinez-Barrio, J.
    Molina Collada, J.
    Rivera, J.
    Gonzalez, T.
    Monteagudo, I.
    Gonzalez, C.
    Castrejon, I.
    Alvaro-Gracia, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1474 - 1475
  • [6] Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice:: adverse events and other reasons for discontinuation of treatment
    Levalampi, T.
    Korpela, M.
    Vuolteenaho, K.
    Moilanen, E.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 (01) : 6 - 12
  • [7] Hepatitis B virus reactivation among hepatitis C patients treated with directacting antiviral therapies in routine clinical practice
    Loggi, Elisabetta
    Gitto, Stefano
    Galli, Silvia
    Minichiello, Mario
    Conti, Fabio
    Grandini, Elena
    Scuteri, Alessandra
    Vitale, Giovanni
    Di Donato, Roberto
    Cursaro, Carmela
    Furlini, Giuliano
    Andreone, Pietro
    JOURNAL OF CLINICAL VIROLOGY, 2017, 93 : 66 - 70
  • [8] Patient Reasons for Initiating or Delaying Hepatitis C Virus (HCV) Treatment and Physician Reasons for Selecting an HCV Treatment: A Prospective Observational Study
    Szabo, Shelagh M.
    Walker, David R.
    Juday, Timothy R.
    Lane, Suzanne
    Saab, Sammy
    HEPATOLOGY, 2015, 62 : 771A - 771A
  • [9] Epidemiology of hepatitis B virus infection among hepatitis C (HCV) infected patients treated within HCV elimination program in Georgia
    Handanagic, Senad
    Butsashvili, Maia
    Shadaker, Shaun
    Tskhomelidze, Irina
    Armstrong, Paige A.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S588 - S588
  • [10] Etanercept and adalimumab in the treatment of RA and SpA in clinical practice. Reasons leading to discontinuation of the treatment
    Levalampi, Tiina
    Korpela, Markku
    Vuolteenaho, Katriina
    Moilanen, Eeva
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 27 - 27
12345